Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

☐ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement

☐ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly

☐ The statistical test(s) used AND whether they were one- or two-sided

☐ Only common tests should be described solely by name; describe more complex techniques in the Methods section.

☐ A description of all covariates tested

☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons

☐ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficients) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)

☐ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted. Give P values as exact values whenever suitable.

☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

☐ Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

- Microsoft Excel & Word-Microsoft Office 2017; Image J 1.52v, NIH; EndNote X9, Thomson Router; R (v 2.15.2); Olympus Confocal FV3000, Olympus; Olympus fluorescence microscope IX70, Olympus; Olympus optical microcscope CX23, Olympus; ACCU-CHEK Performa, Roche Diabetes Care GmbH; ABI PRISM 7900HT Detection Systems, Applied Biosystems

Data analysis

- SPSS (Statistical Product and Service Solutions) Statistics Software (Version 26.0.0.2, Mac OS X Snow Leopard; IBM); Image (Version J1.52g, NIH) was used for quantification of immunoblotting, and positive-staining cells in the fluorescence staining and cell diameter of adipocytes; Image-Pro Plus software (Version 6.0) was used for quantification of cells with positive-staining by immunohistochemistry assay; ABI PRISM 7900HT Detection systems was used for collection of qPCR data. GraphPad Prism Software (Version 8.0 & 9.2.0, Mac OS X Snow Leopard; GraphPad Software) was used for data analysis.

For manuscripts utilizing custom algorithms, software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. Github). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data that support the findings of this study are available.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | Sample size was chosen taking in consideration the means of the target values between the experimental group and the control group, the mean standard error and the statistical analysis used. For animal studies, sample size was defined on the basis of past experience with the models, to allow a power ≥80% at the 5% significance level. For ethical reasons, the minimum number of animals necessary to achieve the scientific objectives was used. |
|---|---|
| Data exclusions | No data were excluded in the current work when performing the final statistical analysis, which have been provided state in "Statistical analysis" section. |
| Replication | All in vitro experiments were performed in triplicate unless specified in the figure legends. The detailed replication of each experiments has been provided in Figure Legend. |
| Randomization | For all in vivo animal studies, all mice were randomly assigned to different treatment groups. |
| Blinding | The investigators were unaware of the experimental groups in all the quantifications. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
|---|---|
| n/a | n/a |
| ☒ | ☒ | Involved in the study | Involved in the study |
| Antibodies | ChIP-seq |
| Eukaryotic cell lines | Flow cytometry |
| Palaeontology and archaeology | MRI-based neuroimaging |
| Animals and other organisms | |
| Human research participants | |
| Clinical data | |
| ☒ | ☒ | Dual use research of concern | |

Antibodies

The primary antibodies against anti-GAPDH (#2118, dilution 1:1000), anti-p-JNK (#4668, dilution 1:1000), anti-JNK (#9258, dilution 1:1000), anti-p38 (#8690, dilution 1:1000), anti-p-I $\beta$B (#2859, dilution 1:1000), anti-κBz (#4814, dilution 1:1000), anti-p-TBK1 (#5483, dilution 1:1000) and anti-p-NF-kB (#3033, dilution 1:500) were obtained from Cell Signaling Technology Inc (CST, Beverly, USA). Antibodies against anti-IKKα (#ab32041, dilution 1:1000), anti-MEK1/2 (#ab178876, dilution 1:1000), anti-p-MEK1/2 (#ab278564, dilution 1:1000), anti-ERK1/2 (#ab184699, dilution 1:1000), anti-p-p38 (#4511, dilution 1:1000), anti-p-IκB $\alpha$ (#2859, dilution 1:1000), anti-IκB $\alpha$ (#4814, dilution 1:1000), anti-p-FAKY397 (#44-624G, dilution 1:1000), anti-p-FAKY576+Y577 (#PA5-37706, dilution 1:1000), anti-FAK (#PA5-88093, dilution 1:1000), anti-p-TAK1 (#PA5-99340, dilution 1:1000), anti-Flag (#MA1-91878, dilution 1:1000), anti-F4/80 (#41-4801-82, dilution 1:200), anti-Ki-67 (#PA5-19462, dilution 1:200) anti-p-ASK1 (#PA5-105027, dilution 1:1000) and anti-ASK1 (#PA5-20200, dilution 1:1000), anti-DUSP8 (PA5-18007, dilution 1:1000), anti-DUSP9 (PA5-106527, dilution 1:1000), anti-DUSP12 (PA5-89113, dilution 1:1000), anti-DUSP14 (PA5-15565, dilution 1:1000), anti-DUSP16 (PA5-23140, dilution 1:1000) and anti-DUSP26 (PA5-22013, dilution 1:1000), anti-Albumin (#PA5-89332, dilution 1:1000) and anti-PECAM (PA5-32321, dilution 1:1000) were purchased from Thermo Fisher Scientific, Inc., Waltham, USA. Antibodies against anti-DUSP22 (#H00056940-B01P, dilution 1:200) and #NBP1-83078, dilution 1:200) were obtained from Novus Biologicals (USA). Secondary antibodies including horseradish peroxidase (HRP)-conjugated anti-rabbit (#Ab6721, dilution 1:5000 for WB, dilution 1:200 for IHC), anti-mouse (#Ab6789, dilution 1:5000) or anti-goat (#Ab6741, dilution 1:5000) were purchased from Abcam (Cambridge, MA, USA). Anti-rabbit IgG H&L
All antibodies used in our study have been validated and detailed information could be found on the websites from manufacturers as listed below:

**IgG (source: Rabbit; reactivity:H M R Mk; Filter:WB IP; https://www.cellsignal.com/products/primary-antibodies/ab124964.html)**

**HNF4a (source: Rabbit; reactivity:H M R; Filter:Flow-Cyt (Intra) WB IHC-P ICC/IF; https://www.abcam.cn/hnf-4-alpha-antibody-ab184699.html)**

**DUSP3 (source: Rabbit; reactivity:H M; Filter:IHC-P WB; https://www.abcam.cn/dusp3-antibody-epr5492-bsa-and-azide-free-ab248113.html)**

**DUSP22 (source: Rabbit; reactivity:H M; Filter:ICC/IF WB; https://www.abcam.cn/dusp22-antibody-ab70124.html)**

**CD11b (source: Rabbit; reactivity:H M R; Filter:WB IHC-P; https://www.abcam.cn/cd11b-antibody-epr1344-ab133357.html)**

**Flag (source: Rabbit; reactivity:Species independent; Filter:WB ICC/IF Flow-Cyt IHC-P IP; https://www.abcam.cn/ddddk-tag-binds-to-ha-tag-sequence-antibody-epr20018-251-ab205606.html)**

** Flag (source: Mouse; reactivity:Species independent; Filter:WB ICC/IF Flow-Cyt IHC-P IP; https://www.abcam.cn/dkkd-tag-binds-to-fk506-antibody-epr19324-461-ab184638.html)**

**CYT (H & L; Alexa Fluor® 488) (#ab150080, dilution 1:300), anti-mouse IgG H&L (Alexa Fluor® 488) (#ab150113, dilution 1:300) or anti-rat IgG H&L (Alexa Fluor® 488) (#ab150165, dilution 1:300) secondary fluorescent antibodies were purchased from Abcam (Cambridge, MA, USA).**
Eukaryotic cell lines

Policy information about cell lines

| Cell line source(s) | Human L02 cells were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China); human hepatic stellate cell (HSC) line LX2 was obtained from Merck Millipore (Shanghai, China); human HCC cell lines (Hep3B and HepG2) and human embryonic kidney 293 T (HEK293T) were obtained from American Type Culture Collection (ATCC; Manassas, USA); and human HCC cell line SMMC-7721 was purchased from the Shanghai Cell Bank Type Culture Collection Committee (CBTCCC, Shanghai, China). All these cell lines have been provided in "Cell Culture" section.
| Authentication | All cell lines have been verified by morphology check under microscopy and short tandem-repeat DNA profiling before the study.
| Mycoplasma contamination | Human L02 cell line, HSC line LX2, HEK293T and human HCC cell lines (Hep3B, HepG2 and SMMC-7721) were used immediately after being received from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China), Merck Millipore (Shanghai, China), ATCC (Manassas, VA, USA) and human embryonic kidney 293 T (HEK293T). All the antibodies used are produced by trusted producers and validation protocols with WB, IP and IHC/IF were available in the website of the companies as well as in previously published papers.
| Commonly misidentified lines (See ICLAC register) | No commonly misidentified cell lines were used in this study.

Animals and other organisms

Policy information about studies involving animals: ARRIVE guidelines recommended for reporting animal research

Laboratory animals

All in vivo experiments were conducted with the age-matched male mice.

Strains:

DUSP22flox/flox mice with C57BL/6N background were constructed using CRISPR/Cas9-regulated genome engineering system. The exon 3 of DUSP22 was selected as conditional knockout region (cKO). Briefly, the selected exon of DUSP22 were flanked by two loxP sites, and therefore two single guide RNAs (gRNA#1 and gRNA#2) targeting DUSP22 introns were designed. The targeting vector containing DUSP22 exon 3 flanked by two loxP sites and the two homology arms was used as the template. The targeting vector, gRNA#1 and gRNA#2, and together with Cas9 were co-injected into fertilized eggs for cKO mouse production. The obtained mice,
which had exon 3 flanked by two KpnI sites on one allele, were used to establish DUSP22lox/lox/flox mice. Hepatocyte-specific DUSP22 deletion (DUSP22HetKO) mice were produced by mating DUSP22lox/flox mice with 6-8-week-old albumin-Cre (Alb-Cre) mice (Jackson Laboratory, Bar Harbor, Maine, USA). A simple schematic diagram has been indicated in Supplementary Fig. S6A.

To obtain mice with conditional knock-in of DUSP22, the RosaDUSP22 mice with C57BL/6N background were constructed using DUSP22 conditional knock-in at the locus of Rosa26 mice by CRISPR/Cas-mediated genome engineering system. In brief, the Rosa26-CAG-loxP-STOP-loxP-mDUSP22-PAK-cassette was cloned into intron 1 of Rosa26. Also, to engineer the targeting vector, homology arms were then constructed by PCR using BAC clone as template. Thereafter, the targeting vector, gRNA, and Cas9 were co-injected into fertilized eggs for RosaDUSP22 mouse production. In indicated experiments, the conditional over-expression of DUSP22 in hepatocyte (DUSP22HetOE) was achieved through injection of adenoviral-associated virus-serotype 8 (AAV8)-thymidine binding globulin (TBG) promoter-Cre recombinase vector (AAV8-TBG-Cre) via intravenous injection and then determined using immunoblotting analysis. A simple schematic diagram has been indicated in Supplementary Fig. S10A. RosaDUSP22 mice littermates without AAV injection were used as controls for the obtained DUSP22HetOE mice.

The hepatocyte-specific FAK-knockout (FAKHetKO) mice with a deletion in the exon 4 of FAK were produced using protocols similar to the one described for the establishment of the DUSP22lox/lox/flox mice and DUSP22HetKO mice. Briefly, FAKlox/flox/mice was designed and constructed by CRISPR/Cas-mediated genome engineering system. The exon 4 of FAK gene was selected as conditional knockout region. To engineer the targeting vector, homology arms and cKO region were generated by PCR using BAC clone from the C57BL/6N library as template. Then Cas9 and RNA was co-injected into fertilized eggs with targeting vector for mouse production. Then, the FAKlox/flox mice were crossed with Alb-Cre mice to produce hepatocyte-specific FAK deficiency mice (FAKHetKO). A simple schematic diagram has been indicated in Supplementary Fig. S21A. FAKlox/flox mice littermates were used as controls for the obtained FAKHetKO mice.

The hepatocyte-specific DUSP22 (DUSP22HetKO) and FAK (FAKHetKO) double deletion (HepDKO) mice were generated through crossing DUSP22lox/lox/flox mice with FAKHetKO mice.

Additionally, all the other normal wild-type (WT) C57BL/6N mice (6- to 8-week-old; 22-25 g body weight) used in the current study were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The age-matched (6- to 8-week-old) male ob/ob mice (#NO90103) were purchased from Nanjing fancied Research Institute of Nanjing University.

Prior to all experiments proper starts, the mice were subjected to adapt to the living environment for 7 days. The mice were housed in a constant temperature, humidity controlled by GRE central air-conditioner, #GMV-Pd250V/Naab-N1, China) and pathogen-free environment (22±2°C, 50-60% humidity) with a standard 12L/12H light/dark cycle. Plenty of water and food (pathogen-free) were available in their cages. The 6-8-week-old WT male mice were fed with high-fat plus high-cholesterol diet (#FC1) (containing 42% saturated-fat, 14% protein, 44% carbohydrates and 0.2% cholesterol w/w) for 24 weeks to induce NASH. The mice fed with a normal chow diet (20% protein, 10% fat and 70% carbohydrate, #D12450H; Research Diets, New Brunswick, NJ, USA) for 24 weeks were defined as controls (NCD).

### Wildanimals

| Our study did not involve wild animals. |

### Field-collected samples

| No field-collected samples were included and used. |

### Ethics oversight

| All mouse experiments and procedures were reviewed and approved by the Institutional Animal Care and Use Committee in Chongqing Key Laboratory of Medicinal Resources in the Three Gorges Reservoir Region, School of Chemical and Biological Engineering, Chongqing University of Education. |

Note that full information on the approval of the study protocol must also be provided in the manuscript.